Basel-based Allegria Therapeutics raised $3.5 million seed round
Allegria Therapeutics, based in Basel, Switzerland, has secured $3.5 million in seed financing led b Forty51 Ventures to advance its innovative treatments for mast cell-mediated diseases. Allegria Therapeutics, founded in 2023 by Forty51 Ventures, is dedicated to revolutionizing the treatment of allergy and mast cell-mediated inflammatory diseases. Maria van Dongen, PhD, a co-founder of the … Read more